All In Biotech

Drug Trial Radar · NCT01626066

Cathepsin Activatable Fluorescent Probe

A Phase I Study of the Safety and Activation of a Cathepsin-Activatable Fluorescent Cancer Specific Probe LUM015

Last checked: Nov 19, 2026Latest source record: Dec 9, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

15

Actual

Start

Jun 2012

Primary completion

Aug 2014

Study completion Aug 2015

Sponsor

Lead sponsor
David KirschAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
American Society of Clinical Oncology
First posted
Jun 22, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
Who can join
All sexes, from 18 years, up to 74 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Real-time detection of cancer cells during surgical removal of a tumor is important. Currently when tissue is removed at the time of surgery, the removed tissue goes to pathology when the margins (edges of the tissue) are examined to see if cancer cells are present. This may take a few to several days. Patients tissue with positive (cancer cells present) margins may require additional therapies including surgery. The purpose of this study is to determine a safe dose of a new imaging agent (LUM015), like a fluorescent contrast agent or dye, that will show in the tumor area during surgery and may help facilitate visualization of tumor for its removal.

Conditions

  • Sarcoma
  • Soft Tissue Sarcoma
  • Breast Cancer

Interventions

  • LUM015Drug

    LUM015 assigned dose given once by IV push

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose of LUM015 in mgTime frame: 24 hours

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Duke University Medical Center

    Durham, North Carolina

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.